---
schema_version: "secwatch.filing_event.v1"
accession: "0001628280-26-044747"
form_type: "8-K"
ticker: "SKYE"
cik: "0001516551"
company_name: "Skye Bioscience, Inc."
filed_at: "2026-06-22T21:53:56+00:00"
generated_at: "2026-06-23T10:06:51.714902+00:00"
event_type: "other_material"
sentiment: "negative"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Skye Bioscience transfers Nasdaq listing to Capital Market after equity deficiency; bid price non-compliance continues

## Summary
- Nasdaq approved transfer from Global to Capital Market effective June 23, 2026 due to stockholders' equity of $9.0M below $10M requirement.
- Company previously disclosed bid price below $1 for 30 consecutive days; compliance period runs to Sept 14, 2026.
- Ticker symbol remains SKYE; transfer to Capital Market allows lower $3M equity standard.
- Company monitoring bid price and considering options but no assurance of regaining compliance.

## SEC filing metadata
- accession: 0001628280-26-044747
- form_type: 8-K
- ticker: SKYE
- cik: 0001516551
- company_name: Skye Bioscience, Inc.
- filed_at: 2026-06-22T21:53:56+00:00
- event_type: other_material
- sentiment: negative
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 8.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1516551/000162828026044747/0001628280-26-044747-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1516551/000162828026044747/skye-20260618.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001628280-26-044747
- JSON: https://secwatch.observer/filing/0001628280-26-044747.json
- Plain text: https://secwatch.observer/filing/0001628280-26-044747.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.